Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses> 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations mediated clinical benefit in platinum resistant ovarian cancer patients, independent of...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI TDS Source Type: news